Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer

• Published in: Respirology case reports Vol. 4; no. 2; pp. e00151 - n/a
• Main Authors: Sekimoto, Yasuhito, Kato, Motoyasu, Shukuya, Takehiko, Koyama, Ryo, Nagaoka, Tetsutaro, Takahashi, Kazuhisa
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2016; John Wiley and Sons Inc
• Subjects: Antigens; Bacterial infections; bevacizumab; Cancer therapies; Case Report; Case reports; Chemotherapy; Drugs; drug‐induced chronic interstitial pneumonia; Growth factors; Immunotherapy; Infections; Lung cancer; Lymphocytes; molecular target drug; Monoclonal antibodies; non‐small cell lung cancer; Patients; Pneumonia; Targeted cancer therapy; Tomography; molecular target drug; bevacizumab; drug‐induced chronic interstitial pneumonia; chemotherapy; non‐small cell lung cancer
• ISSN: 2051-3380; 2051-3380
• DOI: 10.1002/rcr2.151

Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced non‐small cell lung cancer. There are few reports describing bevacizumab‐induced chronic interstitial pneumonia. A 62‐year‐old man with advanced non‐small cell lung cancer was admitted to our hospital with dyspnea. He previously received four courses of carboplatin plus paclitaxel with bevacizumab combination therapy and thereafter received four courses of maintenance bevacizumab monotherapy. A chest‐computed tomography scan on admission revealed diffuse ground glass opacity. He had not received any other drugs and did not have pneumonia. Thus, he was diagnosed with bevacizumab‐induced chronic interstitial pneumonia and was treated with a high dose of corticosteroids. After steroid treatment, his dyspnea and radiological findings improved. This case report is the first description of bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in a patient with non‐small cell lung cancer. Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced non‐small cell lung cancer. Here, we present the first description of bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in a patient with non‐small cell lung cancer